AstraZeneca Group plc Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (49)

Latest Posts

About This Stock More About This Stock
AstraZeneca's Asthma Candidate Shows Promising Results
Article By: Zacks Investment Research
Tuesday, September 12, 2017 12:33 PM EDT
AstraZeneca Plc. announced a subgroup analysis from SIROCCO and CALIMA phase III studies. The studies revealed the efficacy of benralizumab and also showed that this antibody provides increased benefits to patients.
In this article: AZN Also: SNY, REGN
Astrazeneca, Amgen Phase IIb Trial Of Tezepelumab Met Primary Endpoint
Article By: The Fly
Thursday, September 7, 2017 8:20 AM EDT
AstraZeneca and Amgen announced results from the Pathway Phase IIb trial of tezepelumab that they say "showed a significant reduction" in the annual asthma exacerbation rate compared with placebo in patients with severe, uncontrolled asthma.
In this article: AZN, AMGN
AstraZeneca And Takeda Pharmaceutical Company Limited Parkinson's Collaboration
Article By: Samuel Rae
Thursday, August 31, 2017 12:48 PM EDT
AstraZeneca announced that it has put together a deal with Takeda Pharmaceutical Company Limited that will see the two collaborate on the development of a brand-new Parkinson's disease asset.
In this article: AZN, TKPYY Also: RHHBY, PRTA
AstraZeneca And Takeda Ink Deal To Develop Parkinson's Drug
Article By: Zacks Investment Research
Wednesday, August 30, 2017 3:10 PM EDT
AstraZeneca PLC and Takeda Pharmaceutical Company Limited, a Japanese pharma company, have entered into an agreement to jointly develop and commercialize preclinical candidate MEDI1341.
In this article: AZN Also: RHHBY, ACOR, PRTA
Citi Sees Advantage For Tesaro Despite Broad Lynparza Label
Article By: The Fly
Friday, August 18, 2017 6:00 AM EDT
Citi analyst Robyn Karnauskas says the "broad label" given yesterday to AstraZeneca's Lynparza increases competition for Tesaro.
In this article: AZN, TSRO Also: CLVS


Latest Tweets for $AZN

No tweets yet!